RU2553214C2 - Способы очистки однодоменных антигенсвязывающих молекул - Google Patents

Способы очистки однодоменных антигенсвязывающих молекул Download PDF

Info

Publication number
RU2553214C2
RU2553214C2 RU2011112989/10A RU2011112989A RU2553214C2 RU 2553214 C2 RU2553214 C2 RU 2553214C2 RU 2011112989/10 A RU2011112989/10 A RU 2011112989/10A RU 2011112989 A RU2011112989 A RU 2011112989A RU 2553214 C2 RU2553214 C2 RU 2553214C2
Authority
RU
Russia
Prior art keywords
sdab
molecule
protein
carrier
sdab molecule
Prior art date
Application number
RU2011112989/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2011112989A (ru
Inventor
Пол Р. БРАУН
Скотт Андреас ТОБЛЕР
Эндрю М. ВУД
Остин Уэйн БОЕШ
Original Assignee
Аблинкс Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аблинкс Н.В. filed Critical Аблинкс Н.В.
Publication of RU2011112989A publication Critical patent/RU2011112989A/ru
Application granted granted Critical
Publication of RU2553214C2 publication Critical patent/RU2553214C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2011112989/10A 2008-10-29 2009-10-29 Способы очистки однодоменных антигенсвязывающих молекул RU2553214C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10948108P 2008-10-29 2008-10-29
US61/109,481 2008-10-29
PCT/US2009/062651 WO2010056550A1 (en) 2008-10-29 2009-10-29 Methods for purification of single domain antigen binding molecules

Publications (2)

Publication Number Publication Date
RU2011112989A RU2011112989A (ru) 2012-12-10
RU2553214C2 true RU2553214C2 (ru) 2015-06-10

Family

ID=41395476

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011112989/10A RU2553214C2 (ru) 2008-10-29 2009-10-29 Способы очистки однодоменных антигенсвязывающих молекул

Country Status (13)

Country Link
US (2) US10118962B2 (https=)
EP (1) EP2346900A1 (https=)
JP (2) JP6113404B2 (https=)
KR (1) KR20110079693A (https=)
CN (3) CN105646643A (https=)
AU (1) AU2009314311B2 (https=)
BR (1) BRPI0919879A2 (https=)
CA (1) CA2739352C (https=)
HK (1) HK1223377A1 (https=)
IL (1) IL211937A (https=)
MX (1) MX2011004558A (https=)
RU (1) RU2553214C2 (https=)
WO (1) WO2010056550A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
WO2010147686A2 (en) * 2009-03-11 2010-12-23 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
BR112012004054B1 (pt) 2009-10-01 2021-09-08 F. Hoffmann-La Roche Ag Método para produzir um anticorpo anti-her2
WO2011038894A1 (en) * 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
EP2583973B1 (en) * 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
CN103119062A (zh) * 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
PL3279214T3 (pl) 2010-10-29 2025-03-24 Ablynx Nv Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
US9598460B2 (en) 2011-01-18 2017-03-21 University Of Notre Dame Du Lac Antibody purification via affinity chromatography
MX361242B (es) 2011-03-30 2018-11-30 Ablynx Nv Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
BR112014028129A2 (pt) 2012-05-14 2017-06-27 Novo Nordisk As soluções de proteína estabilizadas
WO2014064238A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Method for the separation of proteins containing an albumin-binding
CA2889037C (en) 2012-10-25 2021-06-22 Affibody Ab Abd binding polypeptide
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
US9546208B2 (en) 2014-01-03 2017-01-17 Bio-Rad Laboratories, Inc. Removal of impurities from protein A eluates
US20190202908A1 (en) * 2014-04-15 2019-07-04 President And Fellows Of Harvard College Bi-specific agents
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
SI3337812T1 (sl) 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
EP3337818B1 (en) * 2015-08-21 2026-03-18 F. Hoffmann-La Roche AG Affinity chromatography purification with low conductivity wash buffer
HRP20211737T1 (hr) * 2015-08-21 2022-02-18 F. Hoffmann - La Roche Ag Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji
RU2627849C1 (ru) * 2016-07-22 2017-08-14 Игорь Анатольевич Мнушкин Способ разделения газового потока на отдельные компоненты или фракции
RU2626354C9 (ru) * 2016-07-25 2017-10-04 Игорь Анатольевич Мнушкин Способ разделения газового потока на отдельные компоненты или фракции
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
EP3679066A4 (en) * 2017-09-06 2021-06-09 Airway Therapeutics, Inc. METHOD AND COMPOSITIONS FOR MANUFACTURING SURFACTANT PROTEIN D (SP-D)
US11505601B2 (en) 2017-10-11 2022-11-22 Nanjing Legend Biotech Co., Ltd Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum
EP3749696A1 (en) 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
CN109633053B (zh) * 2018-12-19 2021-04-30 杭州奕安济世生物药业有限公司 细胞培养物蛋白质表达量和蛋白质聚集体量的检测方法
CN112830967B (zh) * 2019-01-10 2022-06-24 瑞阳(苏州)生物科技有限公司 抗hsa单域抗体及其融合蛋白的亲和层析纯化方法
WO2020221781A1 (en) * 2019-04-29 2020-11-05 Cytiva Bioprocess R&D Ab Method for separation of antibodies or antibody fragments being devoid of an fc region capable of binding to protein a
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CN111349159A (zh) * 2020-03-17 2020-06-30 暨南大学 一种抗人血清白蛋白的纳米抗体及其应用
CN115397868A (zh) * 2020-03-30 2022-11-25 埃博灵克斯股份有限公司 用于产生和纯化多价免疫球蛋白单可变域的方法
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用
CN114539351B (zh) * 2022-01-26 2023-03-03 上海健士拜生物科技有限公司 纳米抗体的纯化方法
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法
CN119680525B (zh) * 2024-12-04 2025-09-16 耀海生物技术(北京)有限公司 一种含有人血清白蛋白的填料和构建方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044856A2 (en) * 2003-10-27 2005-05-19 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
WO2006122786A2 (en) * 2005-05-18 2006-11-23 Ablynx Nv Improved nanobodies™ against tumor necrosis factor-alpha
EP1816198A1 (en) * 1995-04-25 2007-08-08 Vrije Universiteit Brussel Variable fragments of immunoglobulins-use for therapeutic or veterinary purposes

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9016299D0 (en) 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
JP3464215B2 (ja) 1991-03-21 2003-11-05 マシモ・コーポレイション 低ノイズ光学プローブ
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0584421A1 (en) 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains
ES2219640T3 (es) 1992-09-24 2004-12-01 Novartis Ag Anticuerpos monoclonales reformados contra un isotopo de inmunoglobulina.
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6350860B1 (en) 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DK1027439T3 (da) * 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
CZ121599A3 (cs) * 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
WO1999064069A1 (en) 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
EP1118669A3 (en) 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
SE0002898L (sv) 2000-08-14 2002-02-15 Telia Ab Kommunikationstjänst
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
EP1332368A2 (en) * 2000-11-03 2003-08-06 Board of Regents, The University of Texas System Methods for detecting the efficacy of anticancer treatments
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
CN1496250A (zh) 2001-03-07 2004-05-12 包括基于重氮盐的化妆品键合剂的局部组合物
PT1384075E (pt) 2001-03-28 2010-03-23 Heska Corp Métodos de detecção de doença renal inicial em animais
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
WO2003020734A2 (en) 2001-08-29 2003-03-13 Amersham Biosciences Corp Labeled nucleoside polyphosphates
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP5138867B2 (ja) * 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
EP1900753B1 (en) * 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US7026432B2 (en) 2003-08-12 2006-04-11 General Electric Company Electrically conductive compositions and method of manufacture thereof
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
ATE485307T1 (de) * 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
EP1869065B1 (en) 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
EP1869067A1 (en) * 2005-04-11 2007-12-26 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CN101287503A (zh) * 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
CN101495136A (zh) 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
WO2007109163A2 (en) * 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
AU2007280929B2 (en) 2006-07-26 2012-03-22 Abbott Rapid Diagnostics International Unlimited Company Analysis device for biological sample
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
WO2008075356A2 (en) 2006-12-19 2008-06-26 Shay Bushinsky Interactive broadcast system and method
WO2008074868A1 (en) 2006-12-20 2008-06-26 Ablynx N.V. Oral delivery of polypeptides
WO2008077945A2 (en) 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2136839A4 (en) 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
US20110287036A1 (en) 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
WO2010060212A1 (en) 2008-11-26 2010-06-03 National Research Council Of Canada Single-domain antibody targeted formulations with superparamagnetic nanoparticles
WO2011003622A1 (en) * 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
US20110097302A1 (en) 2009-07-16 2011-04-28 Ta Tung Yuan Il-1ra-polymer conjugates
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
CN103119062A (zh) 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
EP2603529A1 (en) * 2010-08-13 2013-06-19 Roche Glycart AG Anti-tenascin-c a2 antibodies and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816198A1 (en) * 1995-04-25 2007-08-08 Vrije Universiteit Brussel Variable fragments of immunoglobulins-use for therapeutic or veterinary purposes
WO2005044856A2 (en) * 2003-10-27 2005-05-19 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
WO2006122786A2 (en) * 2005-05-18 2006-11-23 Ablynx Nv Improved nanobodies™ against tumor necrosis factor-alpha

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRENKEN et al., "Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae", Journal of Biotechnology, 2000, 78, стр. 11-21. *
YOSHIHISA HAGIHARA et al, "Stabilization of an Immunoglobulin Fold Domain by an Engineered Disulfide Bond at the Buried Hydrophobic Region", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, vol. 282, no. 50, стp.36489-36495. HARINARAYAN et al., "An exclusion mechanism in ion exchange chromatography", Biotechnology and Bioengineering, 2006, vol.95, no.5, стр.775-787. . *
ОСТЕРМАН Л.А. "Хроматография белков и нуклеиновых кислот", М.: Наука, 1985, стр.270-274, 301-315, 429-434 *

Also Published As

Publication number Publication date
BRPI0919879A2 (pt) 2016-02-16
US20100172894A1 (en) 2010-07-08
EP2346900A1 (en) 2011-07-27
CA2739352A1 (en) 2010-05-20
US11370835B2 (en) 2022-06-28
WO2010056550A1 (en) 2010-05-20
JP2012507557A (ja) 2012-03-29
MX2011004558A (es) 2011-06-01
CN105646643A (zh) 2016-06-08
AU2009314311A1 (en) 2010-05-20
IL211937A0 (en) 2011-06-30
US20190144531A1 (en) 2019-05-16
CA2739352C (en) 2021-07-13
AU2009314311B2 (en) 2013-01-10
KR20110079693A (ko) 2011-07-07
CN102272154A (zh) 2011-12-07
IL211937A (en) 2015-09-24
HK1223377A1 (zh) 2017-07-28
US10118962B2 (en) 2018-11-06
JP2017095503A (ja) 2017-06-01
JP6113404B2 (ja) 2017-04-12
CN118324847A (zh) 2024-07-12
JP6454363B2 (ja) 2019-01-16
RU2011112989A (ru) 2012-12-10

Similar Documents

Publication Publication Date Title
RU2553214C2 (ru) Способы очистки однодоменных антигенсвязывающих молекул
JP7187436B2 (ja) アフィニティークロマトグラフィー洗浄バッファー
JP5567691B2 (ja) Ｆｃ含有タンパク質を精製するためのクロマトグラフィー法
TWI625335B (zh) 純化抗體的方法
US20120149875A1 (en) Affinity chromatography matrix
JP7753105B2 (ja) 抗体の精製方法及びその組成物
HU217850B (hu) Eljárás antitest tisztítására
JP2010209068A (ja) 小モジュラー免疫薬タンパク質を精製する方法
CA3066893A1 (en) Cation exchange chromatography wash buffer
CN105121469A (zh) 用于增加蛋白质的焦谷氨酸形成的方法
EP2670779B1 (en) Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
Abi-Ghanem et al. Immunoaffinity chromatography: a review
US20230136595A1 (en) Method for the production and purification of multivalent immunoglobulin single variable domains
HK40112179A (zh) 单域抗原结合性分子的纯化方法
HK1160474A (en) Methods for purification of single domain antigen binding molecules
WO2026072101A1 (en) Method for purifying biomixtures

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201030